REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
10

My Experience with NAD+ After 3 Months

Jamie Fuller·about 1 month ago
Three months of NAD+ in the books. Here is my honest assessment without the hype. What improved: - Recovery between training sessions (significant) - Sleep quality, particularly deep sleep duration - General sense of wellbeing and mood stability - Skin quality — not something I expected but multiple people commented on it What did not change much: - Strength levels (modest improvement at best) - Body weight (stayed within 2 lbs of starting weight) - Appetite (no noticeable change either direction) Timeline of effects: the first 2-3 weeks were essentially a placebo-free zone. I felt nothing and wondered if I was wasting my time. Week 3-4 is when the sleep improvements kicked in. By week 6, recovery benefits were clear. Weeks 8-12 felt like a plateau but in a good way — consistent benefits without escalation. Would I run it again? Yes, after a break. I think cycling is important both for maintaining sensitivity and for verifying that the benefits were actually from NAD+ and not just other lifestyle factors.

Comments (5)

Shay GoodmanDEMO·about 1 month ago

The timeline you describe is spot on with my NAD+ experience. I also want to emphasize the importance of injection technique. When I switched from 30-gauge to 29-gauge needles and slowed my injection speed, the site irritation essentially disappeared. Small details make a big difference in compliance.

4
Corey IrvingDEMO·about 1 month ago

Following up on my earlier comment about NAD+. I am now 4 weeks past the end of my protocol and wanted to report that about 60 percent of the benefits seem to have persisted. Sleep is still better than baseline, recovery is somewhere between pre-protocol and on-protocol levels. Encouraging for the sustainability question.

5
Adriel DonovanDEMO·about 1 month ago

Great write-up. I have been running a similar NAD+ protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

2
Lux BurnsDEMO·about 1 month ago

This matches my experience with NAD+ almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

3
Gray DuranDEMO·about 1 month ago

Appreciate the honest assessment. Too many NAD+ reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

4

Sign in to comment.